The US FDA granted OST-HER2 rare pediatric disease designation for osteosarcoma in 2021. The US FDA rare pediatric disease PRV program aims to incentivize drug development for rare pediatric diseases.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback